Related articles

Small-cell lung cancer

Aggressive lung cancer with low five-year survival, focus of the DeLLphi-305 trial combining tarlatamab and durvalumab.

• Oncologists in Chicago and Madrid Erupt in Standing Ovations for Breakthroughs Against Pancreatic and Lung Cancer